Francesca Tauceri
A5028852995- Cutaneous Melanoma Detection and Management
- Intraperitoneal and Appendiceal Malignancies
- Immunotherapy and Immune Responses
- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Appendicitis Diagnosis and Management
- Cardiac, Anesthesia and Surgical Outcomes
- Microbial Inactivation Methods
- vaccines and immunoinformatics approaches
- Gastric Cancer Management and Outcomes
- Frailty in Older Adults
- Melanoma and MAPK Pathways
- Gallbladder and Bile Duct Disorders
- Uterine Myomas and Treatments
- Nutrition and Health in Aging
- Neuroendocrine Tumor Research Advances
- Metastasis and carcinoma case studies
- Abdominal Trauma and Injuries
- Abdominal vascular conditions and treatments
- Biliary and Gastrointestinal Fistulas
- Cutaneous lymphoproliferative disorders research
- Genetic factors in colorectal cancer
- Optical Coherence Tomography Applications
- Adrenal and Paraganglionic Tumors
Ospedale G.B. Morgagni - L.Pierantoni
2010-2025
University of Bologna
2022
Zambon (Italy)
2022
King Khalid University
2022
Creative Research Enterprises (United States)
2022
University of Trieste
2008
Abstract Background Accurate quality of life (QoL) data and functional results after cancer surgery are lacking for older patients. The international, multicenter Geriatric Oncology Surgical Assessment Functional rEcovery Surgery (GOSAFE) Study compares QoL before identifies predictors decline in QoL. Methods GOSAFE prospectively collected major elective on adults (≥70 years). Frailty assessment was performed postoperative outcomes recorded (30, 90, 180 days postoperatively) together with by...
The GOSAFE study evaluates risk factors for failing to achieve good quality of life (QoL) and functional recovery (FR) in older patients undergoing surgery colon rectal cancer.
Although standard treatment for advanced epithelial ovarian cancer (EOC) consists of surgical debulking and intravenous platinum- taxane-based chemotherapy, favorable oncological outcomes have been recently reported with the use cytoreductive surgery (CRS) hyperthermic intraperitoneal chemotherapy (HIPEC). The aim study was to analyze feasibility results CRS HIPEC in patients EOC.This is an open, prospective phase 2 including primary or recurrent peritoneal carcinomatosis due EOC....
Abstract Background Dendritic cells (DCs) are the most efficient antigen-presenting and play a central role in immune system, orchestrating response against tumors. We previously demonstrated that DC-based vaccination effectively induces anti-tumor immunity, yet at same time showing robust safety profile, making this treatment potential candidate for effective adjuvant immunotherapy. To explore possibility, we designed randomized phase II trial (EudraCT no. 2014-005123-27) to provide...
<title>Abstract</title> Next-Generation Sequencing (NGS) has transformed cancer research and clinical practice, with Whole Exome (WES) driving advances in mutational profiling personalized oncology. Yet, transcriptomic signatures remain essential for understanding disease mechanisms, including therapy resistance pathways. RNA sequencing (RNA-seq), however, faces unique challenges when dealing low-input or degraded RNA, as often found archival formalin-fixed paraffin-embedded (FFPE) tissues....
Although immunomodulating antibodies are highly effective in metastatic melanoma, their toxicity, related to the activation of T lymphocytes, can be severe. Anticancer vaccines promote a fairly specific response and very well tolerated, but effectiveness has yet demonstrated. We have been treating patients with advanced melanoma an autologous dendritic cell vaccine since 2001; better characterize safety efficacy our product, we designed retrospective study on all treated date....
In this study, we report our experience of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) in patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC), focusing on the factors affecting survival. All surgically treated PC and no involvement other organs referred to institute March 2005 December 2017 were included analysis. Thirty-eight underwent CRS-HIPEC, all had a completeness cytoreduction score 0 (CC0). The median operating time was 645...
Background aimsDendritic cells (DCs) are professional antigen-presenting of the mammalian immune system. Ex vivo differentiated DCs represent a unique Advanced Therapy Medicinal Product (ATMP), used in several clinical trials as personalized cancer immunotherapy. The therapy's reliability depends on its capacity to produce high-quality mature (mDCs) compliance with Good Manufacturing Practices.AimsFrom March 2010 December 2023, 103 patients were enrolled multiple at Immuno-Gene Factory IRCCS...
We reviewed the clinical results of a dendritic cell‐based phase II vaccine trial in stage IV melanoma and analyzed patient subgroup treated with standard therapies after stopping vaccination. From 2003 to 2009, 24 metastatic patients were mature cells pulsed autologous tumor lysate keyhole limpet hemocyanin low‐dose interleukin‐2. Overall response (OR) vaccination was 37.5% benefit 54.1%. All 14 responders showed delayed type hypersensitivity positivity. Median overall survival (OS) 15...
The management of melanoma patients with metastatic in the sentinel nodes (SN) is evolving based on results trials questioning impact completion lymph node dissection (CLND) and demonstrating efficacy new adjuvant treatments. In this landscape, prognostic tools for fine risk stratification are eagerly sought to optimize therapeutic path these patients.A retrospective cohort 2,086 treated CLND after a positive SN biopsy thirteen Italian Melanoma Centers was reviewed. Overall survival (OS)...
This study aimed to improve the understanding of prognostic value tumor mitotic rate (TMR) in cutaneous melanoma and assessed its significance as a predictor for overall, melanoma-specific, recurrence-free survival.This is retrospective multicenter Italian cohort 13,016 patients diagnosed with treated invasive primary between 2005 2020 median follow-up 5.5 years. The survival probability was by Kaplan-Meier method, hazard ratios (HRs), corresponding 95% confidence interval (CI) all-cause...
Skin metastases are an important co-morbidity in melanoma. Despite broad adoption, electrochemotherapy implementation is hindered by a lack of treatment indications, uncertainty regarding procedural aspects, and the absence quality indicators. An expert consensus may harmonize approach among centres facilitate comparison with other therapies.An interdisciplinary panel was recruited for three-round e-Delphi survey. A literature-based 113-item questionnaire proposed to 160 professionals from...
Introduction Surgery is one of the treatments choice for patients with a single metastasis from melanoma but rarely curative. Such could potentially benefit consolidation immunotherapy. Vaccination dendritic cells (DCs) loaded tumour antigens elicits tumour-specific immune response. In our experience, who developed delayed type hypersensitivity (DTH) after DC vaccination showed median overall survival (OS) 22.9 monthsvs4.8 months DTH-negative cases. A phase II randomised trial an advantage...
A patient with resected stage III nodular melanoma treated high-dose interferon-α-b2 adjuvant therapy went on to develop generalized lymphadenopathy and splenomegaly. The total body positron emission tomography showed a high 18F-fluorodeoxyglucose uptake (standardized values >9), indicating possible lymph node spleen malignancies. Histologic examinations of an axillary biopsy osteomedullar were negative, excluding both metastases hematopoietic tumors. symptoms completely regressed after...